Patents Assigned to Legochem Biosciences, Inc.
-
Patent number: 11975076Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.Type: GrantFiled: November 12, 2021Date of Patent: May 7, 2024Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Publication number: 20240131178Abstract: The present disclosure relates to a novel antibody-drug conjugate (ADC) targeting claudin 18 isoform 2 (CLDN18.2), an active metabolite of the ADC, a method of producing the ADC, use of the ADC for the treatment and/or prevention of diseases, and use of the ADC for producing a drug for the treatment and/or prevention of diseases, more specifically hyperproliferative and/or angiogenic diseases, for example, cancer, and more particularly, to an antibody-drug conjugate including a novel antibody or antigen-binding fragment thereof that binds to CLDN18.2, and a pharmaceutical composition including the same.Type: ApplicationFiled: March 30, 2022Publication date: April 25, 2024Applicants: LEGOCHEM BIOSCIENCES, INC., NONA BIOSCIENCES (SUZHOU) CO., LTD.Inventors: Chang Sik PARK, Ho Young SONG, Tae Ik JANG, Chul-Woong CHUNG, Ming-jin JHENG
-
Patent number: 11827703Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: May 9, 2019Date of Patent: November 28, 2023Assignees: LegoChem Biosciences, Inc., NovImmune, SAInventors: Ho Young Song, Yun Hee Park, Sung Min Kim, Hyoung Rae Kim, Ji Hye Oh, Hyun Min Ryu, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim, Maureen Deehan, Nicolas Fischer
-
Patent number: 11707533Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.Type: GrantFiled: July 27, 2020Date of Patent: July 25, 2023Assignees: LegoChem Biosciences, Inc., ABL Bio, Inc.Inventors: Yun-Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-Na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
-
Patent number: 11654197Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.Type: GrantFiled: March 29, 2018Date of Patent: May 23, 2023Assignee: LegoChem Biosciences, Inc.Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun Joung Lee, Ju Young Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
-
Patent number: 11548883Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.Type: GrantFiled: May 15, 2018Date of Patent: January 10, 2023Assignee: LegoChem Biosciences, Inc.Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
-
Patent number: 11413353Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.Type: GrantFiled: November 23, 2016Date of Patent: August 16, 2022Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Patent number: 11173214Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.Type: GrantFiled: November 23, 2016Date of Patent: November 16, 2021Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Patent number: 11167040Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.Type: GrantFiled: November 23, 2016Date of Patent: November 9, 2021Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Patent number: 10980890Abstract: Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.Type: GrantFiled: August 20, 2019Date of Patent: April 20, 2021Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
-
Patent number: 10961242Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.Type: GrantFiled: February 6, 2020Date of Patent: March 30, 2021Assignee: LegoChem Biosciences, Inc.Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
-
Patent number: 10583197Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).Type: GrantFiled: June 2, 2017Date of Patent: March 10, 2020Assignee: LegoChem Biosciences, Inc.Inventors: Yongzu Kim, Taekyo Park, Sungho Woo, Hyangsook Lee, Sunyoung Kim, Jongun Cho, Doohwan Jung, Youngun Kim, Hyunjin Kwon, Kyuman Oh, Yunseo Chung, Yun-Hee Park
-
Publication number: 20190381185Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.Type: ApplicationFiled: November 23, 2016Publication date: December 19, 2019Applicant: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
-
Patent number: 10383949Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.Type: GrantFiled: June 11, 2018Date of Patent: August 20, 2019Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
-
Patent number: 10273235Abstract: Substituted dihydroisoxazole derivatives useful as inhibitors of ?-lactamases are provided. The invention further provides medical uses of substituted dihydroisoxazole derivatives, for example, as antibacterial agents.Type: GrantFiled: March 9, 2018Date of Patent: April 30, 2019Assignee: LegoChem Biosciences, Inc.Inventors: Hye Kyung Chang, Sung Yoon Baek, Min Jung Kim, Kyu Man Oh, Jeung Soon Choi, Soo Bong Ha, Sung Min Kim, Chul-woong Chung, Dae Hyuck Kang, Hyun Jin Kwon, Young Lag Cho, Yong Zu Kim
-
Patent number: 10183997Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.Type: GrantFiled: September 26, 2016Date of Patent: January 22, 2019Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yun Hee Park, Jeong Hee Ryu, Ho Young Song, Jeiwook Chae, Chul-Woong Chung, Ji Eun Jung, Hyo Jung Choi
-
Patent number: 10118965Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor (“EGFR”) antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.Type: GrantFiled: September 26, 2016Date of Patent: November 6, 2018Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Yun Hee Park, Hyo Jung Choi, Ji Eun Jung, Jeong Hee Ryu, Ho Young Song, Jeiwook Chae, Chul-Woong Chung
-
Patent number: 9993568Abstract: Provided are methods of use of compounds comprising a self-immolative group, which compounds may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.Type: GrantFiled: May 27, 2015Date of Patent: June 12, 2018Assignee: LegoChem Biosciences, Inc.Inventors: Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun Hee Park, Jeong Hee Ryu, Kyu Man Oh, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang
-
Patent number: 9988372Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.Type: GrantFiled: July 18, 2014Date of Patent: June 5, 2018Assignees: GREEN CROSS CORPORATION, LEGOCHEM BIOSCIENCES, INC.Inventors: Soongyu Choi, Jungsub Choi, So-Hyun Yoon, Yoo Hoon Kim, Jae Yeon Kim, Suk Ho Lee, Young Lag Cho, Ho Young Song, Dae Yon Lee, Sung Yoon Baek, Sang Eun Chae, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
-
Patent number: 9951072Abstract: Substituted dihydroisoxazole derivatives useful as inhibitors of ?-lactamases are provided. The invention further provides medical uses of substituted dihydroisoxazole derivatives, for example, as antibacterial agents.Type: GrantFiled: September 30, 2016Date of Patent: April 24, 2018Assignee: LegoChem Biosciences, Inc.Inventors: Hye Kyung Chang, Sung Yoon Baek, Min Jung Kim, Kyu Man Oh, Jeung Soon Choi, Soo Bong Ha, Sung Min Kim, Chul-woong Chung, Dae Hyuck Kang, Hyun Jin Kwon, Young Lag Cho, Yong Zu Kim